The promise of longer-lasting immunity: ‘variant-proof’ Covid vaccine begins trials
On-trial jab may offer better protection against new strains of coronavirus
Trials for a “variant-proof” booster vaccine have begun in Manchester, raising hopes that the elderly and vulnerable could achieve long-lasting immunity against Covid-19.
Bolton-based couple Andrew and Helen Clarke, aged 63 and 64 respectively, were the first trial participants to receive the mRNA vaccine, which scientists hope will do away with the need to tweak jabs regularly to combat new strains, The Telegraph reported.
The results of the phase-one trial, which was launched by US pharmaceutical company Gritstone in collaboration with the University of Manchester and the Manchester University NHS Foundation Trust, are expected by the spring.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Most Covid vaccines target the coronavirus’s spike protein – a small grappling hook on the outside of the virus that it uses to latch onto human cells. However, new variants have spike protein mutations, which can make current vaccines less effective.
The new vaccine, currently called GRT-R910, contains other viral proteins that are less likely to evolve over time, and is also designed to induce a strong memory T-cell response.
The University of Manchester’s Professor Andrew Ustianowski, chief investigator for the study, said that “the immune response to first generation vaccines can wane, particularly in older people” and “we think GRT-R910 as a booster vaccination will elicit strong, durable, and broad immune responses”.
Lawrence Young, a virologist and professor of molecular oncology at the University of Warwick, who is not involved in the trial, told The Guardian that “using parts of the virus that are less prone to change in virus variants has the potential to provoke an immune response that will be more effective against all current virus variants and any future variants that might develop”.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
The trial will be broadened to test the jab’s efficacy beyond the elderly and in other vulnerable populations. It will examine dose, safety, tolerability, and immunogenicity at least four months after the second dose of an initial vaccine.
The Clarkes said they had agreed to volunteer for the trial to “play their part” in ending the pandemic.
Andrew Clarke added: “Somebody has to be the first and we’re confident in the science and technology behind this vaccine and convinced of the need for it. We feel that this is perhaps a small part we can play in helping to make things change.”
-
Today's political cartoons - November 21, 2024
Cartoons Thursday's cartoons - wild cards, wild turkeys, and more
By The Week US Published
-
Say Nothing: 'sensational' dramatisation of Patrick Radden Keefe's bestselling book
The Week Recommends The series is a 'powerful reminder' of the Troubles
By The Week UK Published
-
Joy: fertility film starring Bill Nighy offers 'dose of seasonal cheer'
The Week Recommends The film about the invention of the fertility treatment is 'unassuming' but may 'sneak up on you'
By The Week UK Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published
-
Long Covid and chronic pain: is it all in the mind?
The Explainer 'Retraining the brain' could offer a solution for some long Covid sufferers
By The Week UK Published